Background
==========

Primary bone marrow lymphoma (PBML) is an extremely rare form of lymphoma with rapid disease progression and a poor prognosis.[@b1-cmar-11-2553],[@b2-cmar-11-2553] A previous case series study conducted by Martinez et al[@b1-cmar-11-2553] focused on the pathological features of PBML; however, only a few clinical features were found to be associated with the disease. Five different pathological types of lymphoma can originate in the bone marrow, including Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma, not otherwise specified lymphoma (PTCL, NOS), ALK-negative anaplastic large cell lymphoma (ALK-negative ALCL), and follicular lymphoma (FL).[@b1-cmar-11-2553] Among these types, DLBCL is the most common pathological subtype. However, due to the low incidence of the disease, large-scale and systematic case series studies are lacking; therefore, information regarding the clinical features of PBML is lacking. Additionally, the current treatments for PBML are not uniform and have not been standardized, and most treatments focus on only the pathological type and lack specificity and scientific evidence. Furthermore, no study has reported the risk factors affecting the outcomes of PBML. Thus, we reviewed some cases that had been diagnosed at our single center and analyzed previous studies. The present study aimed to investigate the specific clinical features and risk stratification effects on the outcomes of these patients and to discuss treatment strategies for PBML.

Patients and methods
====================

Patient selection and data collection
-------------------------------------

The following criteria were used to define PBML: 1) pathologically confirmed bone marrow involvement, regardless of peripheral blood involvement; 2) absence of lymph node, spleen, liver, or other extra marrow involvement upon physical examination or imaging studies (including thoracic, abdominal, and pelvic enhanced computerized tomography \[CT\], systemic superficial lymph node B-scan ultrasonography, and systemic positron emission tomography/CT \[PET/ CT\]; among these imaging studies, PET/CT is considered relatively authoritative); 3) no evidence of localized bone tumors; 4) bone marrow biopsy with no signs of bony trabecular destruction or PET/CT revealing diffuse enhanced bone marrow metabolism without a localized bone lesion; and 5) exclusion of leukemia/lymphoma cases, including chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia, lymphoplasmacytic lymphoma, hairy cell leukemia, Burkitt lymphoma (Burkitt leukemia variant), and acute lymphoblastic leukemia.[@b1-cmar-11-2553]

In addition to the above mentioned diagnostic criteria, we added the following exclusion criteria: 1) cases with a second tumor or a disease that could seriously influence survival and 2) B-cell lymphomas that could not be further diagnosed.

All patients' clinical data, including sex, age, initial symptoms, peripheral blood indicators at first admission, LDH level, β-2 microglobulin level, international prognostic index, treatment modality, treatment response, and radiological findings, were collected. The bone marrow examination included a bone marrow smear cytologic examination, bone marrow biopsy, and bone marrow aspiration.

This study was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University and was conducted in accordance with the Declaration of Helsinki. Written informed consent for the collection of medical information was obtained from all patients. All procedures performed in the study were in accordance with the ethical standards of the institutional research committee.

Statistical analysis
--------------------

Complete response (CR), partial response (PR), stable disease (SD), and progressive disease were used to define the classification of the treatment response according to the criteria for malignant lymphoma. The overall survival (OS) was defined from the date of pathological diagnosis to death or to the last date of follow-up. We divided the degree of cytopenia into the following four levels: Grade 0: leukocytes ≥4.0×10^9^/L, hemoglobin ≥110 g/L, platelets ≥100×10^9^/L; Grade 1: leukocytes (3.0--3.9)×10^9^/L, hemoglobin (95--100) g/L, platelets (75--99)×10^9^/L; Grade 2: leukocytes (2.0--2.9)×10^9^/L, hemoglobin (80--94) g/L, platelets (50--74)×10^9^/L; Grade 3: leukocytes (1.0--1.9)×10^9^/L, hemoglobin (65--79) g/L, platelets (25--49)×10^9^/L; and Grade 4: leukocytes (0--1.0)×10^9^/L, hemoglobin \<65 g/L, platelets \<25×10^9^/L. OS and survival curves were analyzed by the Kaplan--Meier method. The survival of patients with different prognostic variables was analyzed by the log-rank test, and multiple independent prognostic factors were analyzed using a Cox proportional hazards regression analysis. The correlations between two variables were analyzed by Pearson's chi-square analysis. *P*-values \<0.05 were considered statistically significant, and the statistical analyses were performed using SPSS 21.0.

Results
=======

Patient characteristics in our center
-------------------------------------

Seven patients with PBML who were treated at the Lymphoma Diagnosis and Treatment Center of Henan Province were enrolled between July 2011 and June 2017 into this study; their clinical characteristics are listed in [Table 1](#t1-cmar-11-2553){ref-type="table"}. The median follow-up time was 10.4 months (range: 1.0--25 months) and the median age at diagnosis was 56 years (range: 38--72 years). There were five deaths, accounting for 71.4%. Of these patients, three patients died from treatment failure and other two patients finally succumbed to recurrence of the disease. Notably, PET/CT was used in four cases, and all cases revealed disseminated bone marrow with diffuse hypermetabolism, and the median standard uptake value level was 5.9 (range: 4.8--7.5).

Literature review and statistical analysis
------------------------------------------

Data of 66 cases of PBML were collected and analyzed as follows: 7 cases were among the cases at our center and 59 cases were identified through searching PubMed, China National Knowledge Infrastructure, and Wanfang Data from 1997 to 2018, and the specific information of these patients is presented in [Table 2](#t2-cmar-11-2553){ref-type="table"}. Nineteen of them were excluded due to lack of specific follow-up time; finally, 47 cases were enrolled into this retrospective analysis. As shown in [Table 2](#t2-cmar-11-2553){ref-type="table"}, the female/male ratio of the patients was 4:7 (24:42), and the age ranged between 29 and 81 years (median: 60.0 years; average: 57.6 years). PBML occurred in various pathological types of lymphoma. The most common PBMLs were DLB-CLs with 40 cases (60.6%). The other types included HL (14/66, 21.2%), PTCL, NOS (3/66, 4.5%), ALK-negative ALCL (2/66, 3.0%), and FL (5/66, 7.6%). Six patients with PBML had hemophagocytic lymphohistiocytosis (HLH) at the same time, and the mean survival time was only 4 months. No examples of successful treatment were found in our study. Additionally, four patients had complicated cold agglutinin disease, and these patients usually present with cytopenia accompanied by elevated serum cold agglutinin levels. Finally, three patients were still alive and only one patient died from relapse 19 months after the initial chemotherapy. Of all the 40 cases of DLBCL, we obtained the immunohistochemical results of 39 patients, and these results are shown in [Table 3](#t3-cmar-11-2553){ref-type="table"}. Thirty-three patients died during follow-up, including 20 patients who died from disease progression and 10 patients who died from chemotherapy-related complications. Additionally, 29/57 patients achieved CR, 9/57 patients achieved PR after initial therapy, and the overall response rate was 67.7% (50.9% CR +15.8% PR). PBML of different pathological types showed distinct prognoses. Most patients with HL were treated with doxorubicin, bleomycin, vinblas-tine, and dacarbazine (ABVD) or ABVD-like regimens. The median survival period was 4 months, and HIV-negative HL had a poorer OS than HIV-positive HL (*P*=0.097). However, statistically significant indicators related to prognosis could not be obtained due to insufficient data. The treatment strategies and survival time of the T-cell lymphoma patients were diverse. The median survival period was 9.6 months. Among four out of five patients with FL, only one patient died. Most patients with DLBCL were treated with cyclophosphamide, epirubicin, vincristine, prednisone (CHOP) or a CHOP-like regimen. The median survival period was 19 months. The clinical features of 47 patients included in the retrospective analysis are summarized in [Table 4](#t4-cmar-11-2553){ref-type="table"}. The median OS was 19 months. In the univariable analysis, the Kaplan--Meier method and log-rank test were used to analyze the influence of the following factors on survival: sex, age, degree of cytopenia, serum hemoglobin level, serum leukocyte level, serum platelet level, B symptoms, serum LDH level, serum β2-microglobulin level, and response to initial treatment; the degree of cytopenia, serum platelet level, B symptoms, serum LDH level, and response to initial treatment were found to be significantly correlated with OS (*P*\<0.05; [Table 5](#t5-cmar-11-2553){ref-type="table"}), and the survival curves are shown in [Figure 1](#f1-cmar-11-2553){ref-type="fig"}. Additionally, we attempted to identify the difference in prognosis between HL and non-Hodgkin's lymphoma and between T-cell and B-cell lymphoma; both results were not statistically significant. Due to the limited number of cases, only those factors with *P*-values \<0.05 were studied, including the serum LDH level, B symptoms, serum platelet level, degree of cytopenia, response to initial therapy, and degree of cytopenia\* serum platelet level (which is defined as the interaction of two variables), and the results showed that there was an interaction between the two variables. Considering the *P*-value of the univariable analysis and clinical convenience, we excluded the variable of degree of cytopenia from the Cox regression model. Finally, the LDH level, B symptoms, serum platelet level, and response to initial therapy were included in the Cox regression analysis, and a low serum platelet level, B symptom, and not achieving CR following the initial therapy showed an independent association with an unfavorable OS ([Table 5](#t5-cmar-11-2553){ref-type="table"}). In addition, because of the uniformity of the treatment options for DLBCL, we divided the patients into two groups: one group included 23 cases with RCHOP, RCHOP-like/CHOP, or CHOP-like regimens and the other group included 5 cases with intensive regimens, including HVPERCAVD, EPOCH, ALL, HD-CHOP, and VACOPB. The patients who had received intensive regimens showed a better OS (*P*=0.01; [Figure 2](#f2-cmar-11-2553){ref-type="fig"}).

Discussion
==========

The present study is the largest study concerning PBML to date. To the best of our knowledge, regarding the clinical features and prognosis of primary marrow bone lymphoma, we are the first to perform a systematic and comprehensive review and establish a prognostic model of PBML. PBML has been sporadically reported in the literature since the 1970s. Compared with other lymphomas of the same pathological type, PBML is usually difficult to diagnose, progresses rapidly, and is easy to combine with multiple complications, such as severe infection and HLH, only part of people in the conventional treatment respond well, and OS is relatively short.[@b1-cmar-11-2553]--[@b3-cmar-11-2553] In some cases, a clear diagnosis lacks complete evidence, and often, primary bone lymphoma (PBL) cases, which occur infrequently, are misdiagnosed as PBMLs. Most clinical manifestations of PBLs include bone pain and fractures; most of the common lesion features are destructive through localized radiological examination; and the disease often presents with a local single lesion.[@b1-cmar-11-2553],[@b4-cmar-11-2553] In contrast to PBL, the important symptoms of PBML include cytopenia and B symptoms, and the occurrence of bone pain is relatively rare based on our data. Additionally, in our study, the lesion was usually confined to the marrow cavity during the early stage, and the PET/CT results of 13 patients, not only from our center but also from the literature review, all presented diffuse abnormal fluorodeoxyglucose uptake in the bone marrow that appeared to be more intense in the axial bones; therefore, we believe that PET/CT has a certain importance in the diagnosis of PBML, and so, we added this item to the criteria proposed by Martinez et al[@b1-cmar-11-2553] in 2012. In addition, MRI usually reveals a diffusely abnormal marrow signal (low on T1-weighted images, high on T2-weighted images) in the bone marrow cavity.[@b5-cmar-11-2553] Thus, imaging data can provide important information for the identification of PBL and PBML.

In our studies, three clinical variables were proved to be independent prognostic factors, including B symptoms, serum platelet levels, and response to initial treatment. In several studies about lymphoma, B symptoms have been found to be an important prognostic variable for OS.[@b6-cmar-11-2553]--[@b8-cmar-11-2553] The degree of cytopenia is clearly closely related to disease severity. Therefore, cytopenia likely affects prognosis. However, our results indicate that platelet count was also an independent factor affecting prognosis. In fact, based on our data, thrombocytopenia does not affect treatment or increase the number of bleeding events. Some early studies[@b9-cmar-11-2553]--[@b11-cmar-11-2553] have revealed that thrombocytopenia affects the survival results in lymphomas with bone marrow involvement, including PBML. In addition, a similar prognostic result was reported in early-stage B-cell gastric lymphoma[@b12-cmar-11-2553] and DLBCL.[@b13-cmar-11-2553],[@b14-cmar-11-2553] We believe that autoimmune thrombocytopenia-associated PBML may be a potential cause because autoimmune-induced thrombocytopenia predicted relapse in one-third of lymphoma patients in a study.[@b15-cmar-11-2553] Age, which is a classic risk factor, was no longer associated with the OS in our study. In some conventional studies, older age-associated poor prognosis may be caused by the following three potential factors: multiple comorbidity, lower tolerance to therapy, and multiple organ dysfunction, including bone marrow function.[@b16-cmar-11-2553],[@b17-cmar-11-2553] However, our study indicated that the incidence of complications was nearly equal between the older age group and the younger age group. Additionally, PBML is a disease that severely influences and impairs various organ functions, especially bone marrow function, thereby reducing chemotherapy tolerance. Thus, age seems to be less important than disease malignancy.

Compared with the data from literature review, the incidence of T-cell lymphoma in our center is relatively higher, and the data showed that OS seems to be shorter, which may be associated with a higher rate of B symptoms and HLH. Lymphoma-associated HLH is a relatively vicious disease associated with the uncontrolled activation of the normal immune system,[@b18-cmar-11-2553],[@b19-cmar-11-2553] and another important reason is that only two people achieved CR after initial treatment.

Patients with leukopenia or thrombocytopenia were all administered granulocyte-colony stimulating factor (G-CSF) or recombinant human thrombopoietin, but without success. Hammerstrøm reported that three patients with neutropenia secondary to lymphoid bone marrow involvement responded well to G-CSF before chemotherapy.[@b20-cmar-11-2553] However, we found no other literature confirming this problem. Based on our single-center experience, G-CSF or recombinant human thrombopoietin treatment for cytopenia involving or originating in the bone marrow is usually ineffective.

Most patients with HL were treated with ABVD or an ABVD-like regimen. Unfortunately, more than half of these patients died in the short term, and disease progression was the dominant cause of death. Morita et al[@b21-cmar-11-2553] reported that HIV-negative cases tended to progress rapidly and resulted in worse outcomes, which is consistent with our analysis. Regarding T-cell lymphoma, we first used the gemcitabine, cisplatin, prednisone, and thalidomide regimen in our patients because this regimen was proven to be more efficient than CHOP for the treatment of PTCL in a prospective, randomized, controlled, and open-label clinical trial;[@b22-cmar-11-2553] however, the results were not satisfactory and the results of the CHOP regimen were also not satisfactory. Some reports had mentioned that lymphomas, especially T-cell lymphomas, were the main cause of secondary HLH and were associated with a poorer prognosis.[@b23-cmar-11-2553],[@b24-cmar-11-2553] This condition also appeared in PBML. Among the patients with primary bone marrow T-cell lymphomas, two out of seven (28.6%) patients had HLH complications and died within a month. The clinical use of decitabine in T-cell PBML is a ground-breaking initiative, and the result that patients had increased long-term survival is also promising. Among all PBML cases, the FL cases seemed to show the mildest symptoms and best prognosis, likely due to the slow development of the disease itself. Martinez et al reported a patient who had leukocytosis as the only abnormal indicator at the time of onset and survived for \>5 years until the end of follow-up. In the past two decades, most reported PBMLs have been DLBCLs. Regarding treatment, CHOP or the CHOP-like regimen was usually used as the first-line regimen, and only a small subset of patients (two cases) died from chemotherapy-related side effects during the initial therapy; our results showed that intensive regimens seem to be more effective. We suggest that this effectiveness might be because continuous low concentrations of drugs increased the effectiveness of killing aggressive cancer cells and decreased MDR-1--mediated resistance.[@b25-cmar-11-2553]--[@b28-cmar-11-2553] Additionally, in some studies investigating aggressive non-Hodgkin's lymphoma with high-risk factors, the patients who received intensive chemotherapies actually showed a better OS than those treated with CHOP.[@b29-cmar-11-2553],[@b30-cmar-11-2553] In addition, some studies have published the following results in non-Hodgkin's lymphoma with bone marrow infiltration: the response rate, OS, and progression-free survival of patients treated with intensive regimens were significantly higher than those of patients treated with the standard CHOP regimen.[@b11-cmar-11-2553],[@b31-cmar-11-2553] In conclusion, we believe that intensive therapy may indeed be conducive to survival in PBML. However, another problem that cannot be ignored is that intensive treatment may lead to greater risks in PBML than other high-risk non-Hodgkin lymphomas. Thus, safety and chemotherapy tolerance require extensive data, and the CHOP or CHOP-like regimen remains a relatively safe and moderate regimen. Kazama et al[@b32-cmar-11-2553] reported that a patient who underwent autologous stem cell transplantation (Auto-SCT) after eight cycles of RCHOP survived for \>7 years, representing another clinically significant therapeutic initiative illustrating the possibility that Auto-SCT can improve prognosis. Five cases (case 35, case 39, case 55, case 57, and case 59) developed central nervous system involvement during follow-up, and case 59 developed neurological lesions despite intrathecal prophylaxis, indicating not only that intrathecal treatment is necessary, but also that more valuable therapeutic measures need to be investigated to prevent intracranial progression.

This study had some limitations. First, although we expanded the sample size by reviewing the literature, this study was still a relatively small-scale study, which might have influenced the accuracy of our results. Second, some data were missing in this retrospective study. Third, this study involved less discussion and analysis of target molecules, pathology, and biology.

Conclusion
==========

PBML is a type of lymphoma with a relatively poor prognosis compared to other lymphomas. Patients usually have poor general condition at the time of onset and a poor tolerance to initial chemotherapy during the acute phase. The survival period is generally short. B symptoms, a low serum platelet level (\<75×10^9^/L), and not achieving CR following initial therapy are unfavorable prognosis factors. Additionally, some intensive regimens that differ from traditional regimens or Auto-SCT are worth considering and further exploring. Furthermore, additional and larger prospective multicenter studies are required in the future.
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![Univariable analyses of prognostic factors for OS for our 66 patients with PBML.\
**Notes:** (**A**) Kaplan meier of OS in two groups with and without B symptoms. (**B**) Kaplan meier of OS in two groups with serum platelet level \>75×10^9^/L and with serum platelet level \<75x10^9^/L; (**C**) Kaplan meier of OS in two groups with normal LDH and with elevated LDH; (**D**) Kaplan meier of OS in two groups achieving CR and not achieving CR in the initial therapy; (**E**) Kaplan meier of OS in two groups with hematopoietic function grade 1,2 and hematopoietic function grade 3,4.\
**Abbreviations:** CR, complete response; OS, overall survival; PBML, primary bone marrow lymphoma.](cmar-11-2553Fig1){#f1-cmar-11-2553}

![Curve of cumulative survival of patients with PBML diagnosed as DLBCL with general therapy or with intensive therapy.\
**Notes:** n1 represents the initial number of recipients of the intensive therapy; n2 represents the initial number of recipients of the general therapy.\
**Abbreviations:** DLBCL, diffuse large B-cell lymphoma; OS, overall survival; PBML, primary bone marrow lymphoma.](cmar-11-2553Fig2){#f2-cmar-11-2553}

###### 

Clinical features of seven patients with PBML in our center

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Diagnosis                 Age/sex   Main symptoms                             WBC count (10\^9/L)   Hb (g/ dL)   Platelets (10\^9/L)   LDH   B2MG   IPI   Treatment                                                                                                       Outcome overall   Overall survival (months)
  ------ ------------------------- --------- ----------------------------------------- --------------------- ------------ --------------------- ----- ------ ----- --------------------------------------------------------------------------------------------------------------- ----------------- ---------------------------
  1      PTCL, NOS                 47/F      Cytopenia                                 6.75                  94           30                    N     N      1     3GDPT -- PR\                                                                                                    Dead              18
                                                                                                                                                                   3CHOP -- PD\                                                                                                                      
                                                                                                                                                                   4ESHAP -- PD\                                                                                                                     
                                                                                                                                                                   2DICE -- not been evaluated                                                                                                       

  2      T-cell lymphoma and HLH   38/F      B cytopenia                               0.46                  79           15                    H     H      2     1RCHOP -- not been evaluated\                                                                                   Dead              1
                                                                                                                                                                   1 (Etoposide + dexamethasone + cyclosporine) -- not been evaluated                                                                

  3      T-cell lymphoma           62/M      B cytopenia                               2.07                  85           115                   N     N      3     GDPT×2 -- SD\                                                                                                   Alive             12
                                                                                                                                                                   3CHOP -- PR\                                                                                                                      
                                                                                                                                                                   1 (Decitabine + thalidomide + etoposide + dexamethasone) -- CR                                                                    

  4      DLBCL                     62/M      B cytopenia                               3.2                   60           81                    H     H      4     2REPOCH -- CR\                                                                                                  Alive             25
                                                                                                                                                                   2REPOCH -- CR 2RCHOP -- CR                                                                                                        

  5      DLBCL                     50/F      B cytopenia                               5.3                   99           286                   N     H      2     6RCHOP -- PR -- relapse -- 2 (fotemustine + temozolomide + dexamethasone) -- not been evaluated                 Dead              7

  6      DLBCL and HLH             62/M      B cytopenia, joint pain, chest distress   3.2                   71           3                     H     H      3     1 (Rituximab + methylprednisolone + etoposide) -- not been evaluated                                            Dead              1

  7      DLBCL and HLH             72/M      B cytopenia, fatigue                      9.9                   113          77                    H     H      3     2 (Etoposide + dexamethasone + cyclosporine) -- CR -- relapse -- 2 (etoposide + dexamethasone + cyclosporine)   Dead              9
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:**B, B symptoms; B2MG, β2-microglobulin; CHOP, cyclophosphamide, epirubicin, vincristine, prednisone; CR, complete response; DICE, dexamethasone, ifosfamide, mesna, etoposide; DLBCL, diffuse large B-cell lymphoma; ESHAP, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; GDPT, gemcitabine, cisplatin, prednisone, and thalidomide; H, high; Hb, hemoglobin; HLH, hemophagocytic lymphohistiocytosis; IPI, international prognostic index; N, normal; PBML, primary bone marrow lymphoma; PD, progressive disease; PR, partial response; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; REPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; SD, stable disease; WBC, white blood cells.

###### 

Clinical characteristics of 66 patients with PBML from literature (cases 1--66)

  Case                                             Initial diagnosis           Age (years)   Sex   Initial symptoms                             B2MG   LDH   WBC/Hb/PLT      G    Initial treatment                          IR    OS (months)   Reference
  ------------------------------------------------ --------------------------- ------------- ----- -------------------------------------------- ------ ----- --------------- ---- ------------------------------------------ ----- ------------- ------------------------------------
  1                                                HIV-negative HL             64            M     Fever, cytopenia                             NA     H     2.1/85/61       2    ABVD                                       F     0.1           Ponzoni et al[@b33-cmar-11-2553]
  2                                                HIV-negative HL             50            M     Fever, cytopenia                             NA     H     2.1/74/40       3    ABVD                                       F     0.7           Cacoub et al[@b34-cmar-11-2553]
  3                                                HIV-negative HL             66            F     Fever, cytopenia                             NA     N     2.5/112/132     2    ABVD                                       CR    15.0+         Dholaria et al[@b35-cmar-11-2553]
  4                                                HIV-negative HL and HLH     68            M     Fever, cytopenia                             NA     H     3.2/78/16       4    NO                                         NA    2.0           Yasuyoshi et al[@b21-cmar-11-2553]
  5                                                HIV-positive HL             29            M     Fever, cytopenia                             NA     H     3.2/91/102      2    MOPP/ABV                                   CR    31.0          Gerard et al[@b36-cmar-11-2553]
  6                                                HIV-positive HL             58            M     Fever, cytopenia                             NA     NA    NA              NA   ABVD                                       F     2.0           Ponzoni et al[@b37-cmar-11-2553]
  7                                                HIV-positive HL             36            M     Fever, cytopenia                             NA     NA    NA              NA   ABVD                                       F     4.0           Ponzoni et al[@b37-cmar-11-2553]
  8                                                HIV-positive HL             31            M     Fever, cytopenia                             NA     NA    NA              NA   ABVD                                       CR    18.0+         Ponzoni et al[@b37-cmar-11-2553]
  9                                                HIV-positive HL             49            M     Fever, cytopenia                             NA     NA    NA              NA   ABVD                                       CR    114.0+        Ponzoni et al[@b37-cmar-11-2553]
  10                                               HIV-positive HL             33            M     Fever, cytopenia                             NA     NA    NA              NA   EBV                                        NA    4.0           Ponzoni et al[@b37-cmar-11-2553]
  11                                               HIV-positive HL             34            M     Fever, cytopenia                             NA     NA    NA              NA   ABVD                                       CR    3.0+          Ponzoni et al[@b37-cmar-11-2553]
  12                                               HIV-positive HL             55            M     Fever, chills, weight loss, cytopenia        NA     NA    NA              NA   NA                                         NA    NA            Salama et al[@b38-cmar-11-2553]
  13                                               HIV-positive HL             43            M     Fever, cytopenia, vomiting                   NA     NA    2.1/90/115      2    ABVD                                       NA    1.0+          Shah et al[@b39-cmar-11-2553]
  14                                               HL                          89            F     Fever, cytopenia                             NA     NA    NA              3    NA                                         NA    NA            Suzuki et al[@b40-cmar-11-2553]
  15                                               T-cell lymphoma and HLH     38            M     Fever, cytopenia                             H      H     0.46/79/15      4    RCHOP                                      F     1.0           Our case
  16                                               T-cell lymphoma             62            F     Fever, cytopenia                             N      N     2.07/85/115     2    GDPT                                       PR    12.0+         Our case
  17                                               PTCL, NOS                   34            M     Hypercalcemia                                NA     H     NA              NA   ALL                                        F     9.6           Martinez et al[@b1-cmar-11-2553]
  18                                               PTCL, NOS                   73            F     Fatigue, malaise, cytopenia                  NA     NA    1.3/76/33       3    Pentostatin                                F     44.4          Martinez et al[@b1-cmar-11-2553]
  19                                               PTCL, NOS                   47            M     Cytopenia                                    N      N     6.75/94/30      3    3GDPT                                      PR    18.0          Our case
  20                                               ALK-negative ALCL and HLH   60            M     Fever, jaundice, cytopenia                   NA     NA    1.7/N/107       3    Cortisol + cyclosporine                    F     NA            Gudgin et al[@b41-cmar-11-2553]
  21                                               ALK-negative ALCL           60            M     Fever, cytopenia                             H      N     1.5/86/105      3    1CHOP                                      CR    NA            Szomoret al[@b42-cmar-11-2553]
  22                                               FL                          76            M     NO                                           N      N     13.65/140/216   0    NO                                         NA    64.8+         Martinez et al[@b1-cmar-11-2553]
  23                                               FL                          81            F     Cytopenia                                    H      H     19.9/73/67      3    COP                                        F     3.6           Martinez et al[@b1-cmar-11-2553]
  24                                               FL                          61            F     Bone pain                                    N      N     7.1/132/236     0    RCHOP                                      CR    40.8+         Martinez et al[@b1-cmar-11-2553]
  25                                               FL                          55            M     Cytopenia                                    N      H     11.4/97/300     1    RCHOP                                      CR    12.0+         Martinez et al[@b1-cmar-11-2553]
  26                                               FL                          78            M     Hemorrhage, cytopenia                        NA     N     8.6/75/1        4    THP-COP                                    PR    NA            Kagoya et al[@b43-cmar-11-2553]
  27                                               DLBCL and HLH               62            F     Fever, joint pain, cytopenia, chest stress   H      H     3.2/71/3        4    R+methylprednisolone + etoposide           F     1.0           Our case
  28                                               DLBCL and HLH               72            F     Fever, fatigue, cytopenia                    H      H     9.9/113/77      1    Etoposide + dexamethasone + cyclosporine   CR    9.0           Our case
  29                                               DLBCL and HLH               57            M     Fever, weight loss, cytopenia                H      H     4.8/65/68       3    RCHOP                                      CR    10.0+         Kim et al[@b24-cmar-11-2553]
  30                                               DLBCL and CAD               70            F     Cytopenia, jaundice                          NA     H     5.9/4.6/331     4    RCHOP                                      CR    22.0+         Kosugi et al[@b44-cmar-11-2553]
  31                                               DLBCL and CAD               75            F     Cytopenia                                    NA     NA    NA              NA   RCHOP                                      CR    NA            Sumi et al[@b45-cmar-11-2553]
  32                                               DLBCL and CAD               76            M     Fever, cytopenia, jaundice                   NA     H     5.3/74/NA       NA   RCHOP                                      CR    19.0          Yamashita et al[@b3-cmar-11-2553]
  33                                               DLBCL and CAD               69            M     Fatigue, somnolence, cytopenia               NA     H     NA/80/NA        NA   RCHOP                                      CR    NA            Níáinle et al[@b46-cmar-11-2553]
  34                                               DLBCL                       62            F     Cytopenia                                    H      H     3.2/70/81       4    REPOCH                                     CR    25.0+         Our case
  35                                               DLBCL                       50            M     Fever, cytopenia                             N      H     5.3/99/286      1    RCHOP                                      PR    7.0           Our case
  36                                               DLBCL                       70            F     Fatigue, cytopenia                           NA     NA    5.4/81/67       2    NA                                         F     NA            Huimin et al[@b47-cmar-11-2553]
  37                                               DLBCL                       60            F     Fever, cytopenia                             NA     NA    0.58/71/176     4    RCHOP                                      CR    NA            Huimin et al[@b47-cmar-11-2553]
  38                                               DLBCL                       56            M     Fatigue, cytopenia                           NA     NA    2.84/73/33      3    RCHOP                                      4CR   NA            Huimin et al[@b47-cmar-11-2553]
  39                                               DLBCL                       58            M     Fever, fatigue, cytopenia                    NA     H     52.8/106/21     4    RCHOP                                      CR    19.0          Wang et al[@b48-cmar-11-2553]
  40                                               DLBCL                       41            M     Fever, joint pain, weight loss, cytopenia    NA     H     2.75/100/NA     NA   CHOEP                                      PR    10.0          Ren et al[@b49-cmar-11-2553]
  41                                               DLBCL                       56            M     Cytopenia, jaundice                          H      N     1.9/41/62       4    RCHOP                                      NA    40.0+         Hu et al[@b50-cmar-11-2553]
  42                                               DLBCL                       52            F     Cytopenia                                    NA     NA    8.1/60/386      4    RCHOP                                      NA    NA            Bhagat et al[@b2-cmar-11-2553]
  43                                               DLBCL                       52            F     Cytopenia                                    NA     NA    2.3/77/48       3    RCHOP                                      F     NA            Bhagat et al[@b2-cmar-11-2553]
  44                                               DLBCL                       64            M     Cytopenia                                    NA     NA    4.8/60/27       4    Chlorambucil + prednisolone                NA    NA            Bhagat et al[@b2-cmar-11-2553]
  45                                               DLBCL                       51            F     Cytopenia                                    NA     NA    1.9/81/24       4    RCHOP                                      CR    NA            Bhagat et al[@b2-cmar-11-2553]
  46                                               DLBCL                       76            F     Dyspnea, cytopenia                           NA     H     NA              NA   RCHOP                                      CR    27.0+         Niscola et al[@b51-cmar-11-2553]
  47                                               DLBCL                       52            F     Cytopenia                                    NA     N     8.1/60/286      4    NA                                               NA            Sharma et al[@b52-cmar-11-2553]
  48[a](#tfn2-cmar-11-2553){ref-type="table-fn"}   DLBCL                       39            F     Fever, cytopenia                             NA     N     2.95/65/NA      NA   RCHOP                                      CR    NA            Kazama et al[@b32-cmar-11-2553]
  49                                               DLBCL                       44            M     Fever, cytopenia                             N      H     NA              NA   CHOP                                       NA    8.0           Chang et al[@b53-cmar-11-2553]
  50                                               DLBCL                       65            M     B, cytopenia                                 H      N     3.5/102/56      2    RCHOP                                      CR    20.4+         Martinez et al[@b1-cmar-11-2553]
  51                                               DLBCL                       63            F     Fatigue, cytopenia                           H      H     2.8/97/121      2    HD-CHOP                                    PR    54.0          Martinez et al[@b1-cmar-11-2553]
  52                                               DLBCL                       29            M     Malaise, cytopenia                           H      H     1.7/82/66       3    CHOP                                       F     7.2           Martinez et al[@b1-cmar-11-2553]
  53                                               DLBCL                       63            F     Bone pain, fatigue, cytopenia, malaise       N      H     5.1/89/207      2    COP                                        PR    21.6          Martinez et al[@b1-cmar-11-2553]
  54                                               DLBCL                       71            F     Fatigue                                      H      H     NA              NA   RCHOP                                      CR    18.0          Martinez et al[@b1-cmar-11-2553]
  55                                               DLBCL                       45            M     Bone pain                                    NA     NA    NA              NA   RCHOP                                      F     7.2           Martinez et al[@b1-cmar-11-2553]
  56                                               DLBCL                       72            M     Fatigue, cytopenia                           NA     H     5.2/52/221      4    RCHOP                                      F     4.8+          Martinez et al[@b1-cmar-11-2553]
  57                                               DLBCL                       67            M     Infections, cytopenia                        NA     H     2.6/108/61      2    ALL                                        F     28.8          Martinez et al[@b1-cmar-11-2553]
  58                                               DLBCL                       32            M     Bone pain, fatigue, malaise, cytopenia       NA     H     3.7/106/162     1    VACOPB                                     CR    105.6+        Martinez et al[@b1-cmar-11-2553]
  59                                               DLBCL                       78            F     B, cytopenia                                 NA     H     22.5/120/67     3    RCHOP                                      CR    4.0           Alvares et al[@b54-cmar-11-2553]
  60                                               DLBCL                       73            F     B, cytopenia                                 H      H     7.7/110/46      3    CHOP                                       F     NA            Alvares et al[@b54-cmar-11-2553]
  61                                               DLBCL                       42            M     B, fatigue, cytopenia                        NA     H     2.3/105/50      2    RCHOP                                      F     NA            Alvares et al[@b54-cmar-11-2553]
  62                                               DLBCL                       51            M     Bone pain, fatigue, malaise, cytopenia       NA     H     3.7/117/273     1    CHOP                                       F     12.0          Martinez et al[@b1-cmar-11-2553]
  63                                               DLBCL                       79            M     Bone pain, fatigue, malaise, cytopenia       NA     H     4.5/87/500      2    RCHOP                                      CR    18.0+         Martinez et al[@b1-cmar-11-2553]
  64                                               DLBCL                       70            M     B, bone pain, cytopenia                      N      N     2.8/63/173      4    CHOEP                                      PR    9.0           Martinez et al[@b1-cmar-11-2553]
  65                                               DLBCL                       67            M     Fever, cytopenia                             NA     NA    N/71/N          NA   NA                                         NA    NA            Nagasaki et al[@b55-cmar-11-2553]
  66                                               DLBCL                       40            M     Fatigue, dyspnea, cytopenia                  NA     H     NA/43/NA        NA   HYPERCAVD                                  CR    33.0+         Matthieset al[@b5-cmar-11-2553]

**Notes:**

Recieved autologous stem cell transplantation. + Alive.

**Abbreviations:**ALL, prednisone, vincristine, daunorubicin, L-asparaginase, cyclophosphamide, cytarabine, bleomycin, 6-mercaptopurine; ALK-negative ALCL, ALK-negative anaplastic large cell lymphoma; B, B symptoms; B2MG, β2-microglobulin; CAD, cold agglutinin disease; CHOEP, cyclophosphamide, doxorubicin, vincristine, prednisolone, etoposide; CHOP, cyclophosphamide, epirubicin, vincristine, prednisone; COP, cyclophosphamide, vincristine, prednisone; CR, complete response; DLBCL, diffuse large B-cell lymphoma; EBV, epiadriamicin, bleomicin, vinblastin; F, failure; FL, follicular lymphoma; G, hematopoietic function grade; GDPT, gemcitabine, cisplatin, prednisone, and thalidomide; H, high; Hb, hemoglobin; HD, high dose; HL, Hodgkin's lymphoma; HLH, hemophagocytic lymphohistiocytosis; HYPERCAVD, cyclophosphamide, vincristine, dexamethasone, adriamycin/methotrexate, cytarabine; IR, initial response; MOPP/ABV, metchlorethamine, vincristine, cyclophosphamide, prednisone/adriamycin, bleomycin, vinblastin; N, normal; NA, not available; OS, overall survival; PLT, platelets; PR, partial response; PTCL, NOS, peripheral T-cell lymphoma, not otherwise specified; RCHOP, rituximab,cyclophosphamide, epirubicin, vincristine, prednisone; REPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; THP-COP, pirarubicin, cyclophosphamide, vincristine, prednisolone; VACOPB, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin; WBC, white blood cells.

###### 

Pathological, phenotypic, and molecular features of DLBCL cases (n=34)

  Case   CD20   CD10   CD5   BCL-2   BCL-6   Involvement (%)
  ------ ------ ------ ----- ------- ------- -----------------
  27     \+     NA     NA    NA      NA      NA
  28     \+     NA     NA    NA      NA      NA
  29     \+     −      \+    −       \+      65.4
  30     \+     −      −     \+      NA      NA
  31     \+     −      −     \+      NA      NA
  32     \+     −      −     \+      \+      NA
  33     \+     −      −     NA      NA      NA
  34     NA     NA     NA    NA      NA      NA
  35     \+     NA     NA    NA      NA      NA
  36     \+     −      NA    \+      −       36.7
  37     \+     −      \+    \+      −       9.78
  38     \+     \+     −     NA      \+      18.4
  39     \+     −      −     \+      −       39
  40     \+     \+     −     NA      NA      NA
  41     \+     −      −     NA      NA      4.5
  42     \+     −      NA    NA      NA      35
  43     \+     −      NA    NA      NA      42
  44     \+     −      NA    NA      NA      50
  45     \+     −      NA    NA      NA      50
  46     \+     NA     NA    \+      NA      NA
  47     \+     NA     NA    −       \+      NA
  48     \+     NA     −     −       NA      NA
  49     \+     NA     \+    NA      NA      23.5
  50     \+     −      −     −       −       70
  51     \+     −      −     \+      NA      90
  52     \+     −      −     \+      −       20
  53     \+     −      −     \+      −       15
  54     \+     \+     −     \+      \+      80
  55     \+     −      −     \+      −       70
  56     \+     −      −     \+      −       80
  57     \+     −      −     \+      −       70
  58     \+     NA     −     NA      NA      100
  59     \+     NA     −     NA      NA      80
  60     \+     −      −     NA      NA      70
  61     \+     −      −     NA      NA      70
  62     \+     \+     −     \+      NA      80
  63     \+     −      −     \+      \+      90
  64     \+     NA     −     NA      NA      100
  65     \+     −      \+    NA      NA      35
  66     −      NA     NA    NA      NA      25--75

**Abbreviations:** DLBCL, diffuse large B-cell lymphoma; NA, not applicable.

###### 

Clinical characteristics of 47 patients with PBML

  Variable                          Total, n   Percentage (%)
  --------------------------------- ---------- ----------------
  Age (years)                                  
   ≤60                              24         51.1
   \>60                             23         48.9
  Sex                                          
   Male                             33         70.2
   Female                           14         29.8
  Degree of cytopenia                          
   Grades 1and 2                    18         52.9
   Grades 3 and 4                   16         47.1
  Serum hemoglobin level (g/L)                 
   ≤75                              11         30.6
   \>75                             25         69.4
  Serum leukocyte level (10\^9/L)              
   ≤4.0                             22         62.9
   \>4.0                            13         37.1
  Serum platelet level (10\^9/L)               
   ≤75                              15         45.5
   \>75                             18         54.5
  Serum LDH level                              
   Normal                           8          21.1
   High                             30         78.9
  Serum β2-microglobulin level                 
   Normal                           9          45
   High                             11         55
  B symptoms                                   
   Yes                              26         55.3
   No                               21         44.7
  Response to initial treatment                
   CR                               20         48.8
   Not CR                           21         51.2

**Abbreviations:**CR, complete remission; PBML, primary bone marrow lymphoma.

###### 

Univariate and multivariate analyses for overall survival

  Variable                          Univariate analysis   Multivariate analysis    *P*-value
  --------------------------------- --------------------- ------------------------ -----------
  Age (years)                       0.549                                          
   ≤60                                                                             
   \>60                                                                            
  Sex                               0.584                                          
   Male                                                                            
   Female                                                                          
  Degree of cytopenia               0.041                                          
   Grades 1 and 2                                                                  
   Grades 3 and 4                                                                  
  Serum hemoglobin level (g/L)      0.93                                           
   ≤75                                                                             
   \>75                                                                            
  Serum leukocyte level (10\^9/L)   0.823                                          
   ≤4.0                                                                            
   \>4.0                                                                           
  Serum platelet level (10\^9/L)    0.06                                           
   ≤75                                                    4.553 (1.371--15.125)    0.013
   \>75                                                                            
  Serum LDH level                   0.048                                          
   High                                                                            
   Normal                                                                          
  Serum β2- microglobulin level     0.615                                          
   High                                                                            
   Normal                                                                          
  B symptoms                        0.037                                          
   Yes                                                    1.4229 (2.891--70.031)   0.001
   No                                                                              
  Response to initial treatment     \<0.001                                        
   Not CR                                                 12.429 (2.871--53.802)   0.001
   CR                                                                              

**Abbreviation:**CR, complete remission.
